133 related articles for article (PubMed ID: 3625598)
1. Opposite regulation of serotonin-S2 and dopamine-D2 receptors in rat brain following chronic receptor blockade.
Leysen JE; Van Gompel P; de Chaffoy de Courcelles D; Niemegeers CJ
J Recept Res; 1987; 7(1-4):223-39. PubMed ID: 3625598
[TBL] [Abstract][Full Text] [Related]
2. Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone.
Leysen JE; Van Gompel P; Gommeren W; Woestenborghs R; Janssen PA
Psychopharmacology (Berl); 1986; 88(4):434-44. PubMed ID: 3010361
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation of dopamine-D2 and serotonin-S2 receptors by chronic treatment with the serotonin-S2 antagonists, ritanserin, and setoperone.
Leysen JE; van Gompel P; Gommeren W; Laduron PM
Psychopharmacol Ser; 1987; 3():214-24. PubMed ID: 2950521
[No Abstract] [Full Text] [Related]
4. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.
Leysen JE; Gommeren W; Van Gompel P; Wynants J; Janssen PF; Laduron PM
Mol Pharmacol; 1985 Jun; 27(6):600-11. PubMed ID: 2860558
[TBL] [Abstract][Full Text] [Related]
5. Functional interaction between serotonin-S2 and dopamine-D2 neurotransmission as revealed by selective antagonism of hyper-reactivity to tryptamine and apomorphine.
Awouters F; Niemegeers CJ; Megens AA; Janssen PA
J Pharmacol Exp Ther; 1990 Sep; 254(3):945-51. PubMed ID: 1697623
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF
J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
[TBL] [Abstract][Full Text] [Related]
7. Receptor interactions of dopamine and serotonin antagonists: binding in vitro and in vivo and receptor regulation.
Leysen JE; Gommeren W; Janssen PF; Van Gompel P; Janssen PA
Psychopharmacol Ser; 1988; 5():12-26. PubMed ID: 3045796
[TBL] [Abstract][Full Text] [Related]
8. [Role of serotonin and dopamine receptors in the mechanism of action of haloperidol and pirenperone].
Maĭmets MO; Vasar EE; Nurk AM; Allikmets LKh
Farmakol Toksikol; 1985; 48(2):15-8. PubMed ID: 3996566
[TBL] [Abstract][Full Text] [Related]
9. 5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade.
Saller CF; Czupryna MJ; Salama AI
J Pharmacol Exp Ther; 1990 Jun; 253(3):1162-70. PubMed ID: 2141636
[TBL] [Abstract][Full Text] [Related]
10. Effects of chronic administration of ondansetron (GR38032F), a selective 5-HT3 receptor antagonist, on monoamine metabolism in mesolimbic and nigrostriatal dopaminergic neurons and on striatal D2-receptor binding.
Koulu M; Lappalainen J; Hietala J; Sjöholm B
Psychopharmacology (Berl); 1990; 101(2):168-71. PubMed ID: 2140903
[TBL] [Abstract][Full Text] [Related]
11. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity.
Szczepanik AM; Brougham LR; Roehr JE; Conway PG; Ellis DB; Wilmot CA
J Pharmacol Exp Ther; 1996 Aug; 278(2):913-20. PubMed ID: 8768747
[TBL] [Abstract][Full Text] [Related]
13. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics.
Mita T; Hanada S; Nishino N; Kuno T; Nakai H; Yamadori T; Mizoi Y; Tanaka C
Biol Psychiatry; 1986 Dec; 21(14):1407-14. PubMed ID: 2947636
[TBL] [Abstract][Full Text] [Related]
14. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
Hess EJ; Albers LJ; Le H; Creese I
J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo irreversible blockade of cortical S2 serotonin receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline: a technique for investigating S2 serotonin receptor recovery.
Battaglia G; Norman AB; Newton PL; Creese I
J Neurochem; 1986 Feb; 46(2):589-93. PubMed ID: 2934516
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of tryptamine binding sites following chronic molindone administration. A comparison with responses of dopamine and 5-hydroxytryptamine receptors.
Nguyen TV; Juorio AV
Naunyn Schmiedebergs Arch Pharmacol; 1989 Oct; 340(4):366-71. PubMed ID: 2586632
[TBL] [Abstract][Full Text] [Related]
17. Changes in rat dopamine- and serotonin function in vivo after prolonged administration of the specific 5-HT uptake inhibitor, citalopram.
Arnt J; Overø KF; Hyttel J; Olsen R
Psychopharmacology (Berl); 1984; 84(4):457-65. PubMed ID: 6441945
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationships of 4-amino-5-chloro-N-(1,4-dialkylhexahydro-1,4-diazepin-6-yl)-2-methoxybenzamide derivatives, novel and potent serotonin 5-HT3 and dopamine D2 receptors dual antagonist.
Hirokawa Y; Harada H; Yoshikawa T; Yoshida N; Kato S
Chem Pharm Bull (Tokyo); 2002 Jul; 50(7):941-59. PubMed ID: 12130853
[TBL] [Abstract][Full Text] [Related]
19. The serotonin 5-HT(2A) receptor subtype does not mediate apomorphine-induced aggressive behaviour in male Wistar rats.
Skrebuhhova-Malmros T; Pruus K; Rudissaar R; Allikmets L; Matto V
Pharmacol Biochem Behav; 2000 Oct; 67(2):339-43. PubMed ID: 11124399
[TBL] [Abstract][Full Text] [Related]
20. Molecular and behavioral effects mediated by Gs-coupled adenosine A2a, but not serotonin 5-Ht4 or 5-Ht6 receptors following antipsychotic administration.
Ward RP; Dorsa DM
Neuroscience; 1999 Mar; 89(3):927-38. PubMed ID: 10199625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
